Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease

Official Title: “Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease.”

Atypical hemolytic uraemic syndrome is caused by defects in the regulating factors in the alternative pathway of the complement system. Triggering can cause an uncontrolled complement activation with endothelial damage and thrombotic micro-angiopathy, especially in the kidneys. This can result in endstage renal failure. Complement activation during hemodialysis has been described as a result of contact between blood and the dialysis membrane. Our hypothesis is that patients with atypical hemolytic uraemic syndrome have a stronger complement activation during hemodialysis than patients with another underlying kidney disease. This could be a reason to treat patients with endstage renal failure due to atypical hemolytic uraemic syndrome preferentially with peritoneal dialysis instead of hemodialysis.

Arms, Groups and Cohorts in this Clinical Trial

• : cases
  • patients with endstage renal failure due to atypical uraemic syndrome treated with hemodialysis.
• : controls
  • patiënts with endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.

Primary Measures

• C3a-des-Arg measuring (as a marker of activation).
  • Time Frame: at time 0, at 15 minutes, at 60 minutes and at 180 minutes
    Safety Issue?: No
• white blood cell count
  • Time Frame: before and after 15 minutes of hemodialysis
    Safety Issue?: No

Inclusion Criteria:

• cases: endstage renal failure due to atypical hemolytic uraemic syndrome treated with hemodialysis.
• controls: endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: University Hospital, Ghent Other

Overall Clinical Trial Officials and Contacts

Raymond Vanholder, MD, PhD Principal Investigator University Hospital, Ghent  

Overall Contact: Rogier Caluwé, MD  rogier.caluwe@uzgent.be

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00930423

Study ID Number: 2009/270

ClinicalTrials.gov Identifier: NCT00930423

Health Authority: Belgium: Institutional Review Board

website of the University Hospital Ghent